Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world post-marketing study of rhTNK-tPA for hyperacute ischemic stroke
ChiCTR2400083596Phase 4Recruiting
- Sponsor
- Linyi People's Hospital
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenecteplase in ischemic stroke, sponsored by Linyi People's Hospital. Primary endpoints: Symptomatic intracranial hemorrhage within 36 hours and Favorable functional outcome at 90 days. Started Apr 2024; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400083596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083596.